ストックスクリーナーアプリを入手
12.18
0.83%
0.10
アフターアワーズ：
12.45
0.27
+2.22%
Intellia Therapeutics Inc (NTLA) 最新ニュース
Cathie Wood's ARK buys Intellia, sells Tesla in latest stock trades - Investing.com
Intellia Crashes 60% in a Year: How Should You Play the Stock? - Nasdaq
First Week of February 2025 Options Trading For Intellia Therapeutics (NTLA) - Nasdaq
Barclays PLC Buys 44,022 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) - MarketBeat
Intellia Therapeutics (NASDAQ:NTLA) Sets New 12-Month LowHere's What Happened - MarketBeat
3 Things You Need to Know if You Buy CRISPR Therapeutics Today - AOL
State Street Corp Raises Stock Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA) - MarketBeat
(NTLA) Proactive Strategies - Stock Traders Daily
Intellia Therapeutics' SWOT analysis: gene editing stock faces pivotal year - Investing.com
Intellia Therapeutics' SWOT analysis: gene editing stock faces pivotal year By Investing.com - Investing.com UK
Short Interest in Intellia Therapeutics, Inc. (NASDAQ:NTLA) Rises By 15.5% - MarketBeat
Wellington Management Group LLP Has $13.25 Million Stock Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA) - MarketBeat
Intellia Therapeutics (NASDAQ:NTLA) Shares Down 4.2%Here's What Happened - MarketBeat
Intellia stock touches 52-week low at $12.81 amid biotech slump - Investing.com
The Right Fit: What BMS, Intellia Look for in Cell and Gene Therapy Talent - BioSpace
Why Intellia Therapeutics (NTLA) Is the Worst ARK Stock to Buy According to Short Sellers - Insider Monkey
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Intellia Not Entitled to 'Safe Harbor' in BlueAllele Patent Suit - Bloomberg Law
Intellia Can't Escape Patent Suit Over $100M Regeneron Deal - Law360
Two Sigma Advisers LP Buys 257,700 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 52,297 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) - MarketBeat
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Bought by Fmr LLC - MarketBeat
Charles Schwab Investment Management Inc. Acquires 37,714 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) - MarketBeat
Intellia Therapeutics (NASDAQ:NTLA) Stock Price Up 7.5%Time to Buy? - MarketBeat
Benjamin Edwards Inc. Has $1.19 Million Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA) - MarketBeat
Verition Fund Management LLC Purchases 50,763 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) - MarketBeat
(NTLA) Investment Analysis - Stock Traders Daily
Shareholders in Intellia Therapeutics (NASDAQ:NTLA) have lost 88%, as stock drops 4.7% this past week - Simply Wall St
Future-Proofing Growth of Gene Editing Technology Innovation - openPR
Patient Square Capital LP Invests $2.64 Million in Intellia Therapeutics, Inc. (NASDAQ:NTLA) - MarketBeat
Chevy Chase Trust Holdings LLC Sells 231,592 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) - MarketBeat
PDT Partners LLC Reduces Stock Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA) - MarketBeat
BNP Paribas Financial Markets Has $5.06 Million Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA) - MarketBeat
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Intellia Therapeutics Awards Key Executive Inducement Grant with 3-Year Vesting Schedule | NTLA Stock News - StockTitan
CRISPR Technology Market Growth Trends from 2024 to 2033 | Key - openPR
Intellia Therapeutics Announces Promising CRISPR Therapy Results - TipRanks
NTLA Up as FDA Grants RMAT Status to Genome-Editing Therapy - MSN
Cathie Wood Sees $400B Opportunity In Biologics — How Have Her Bets Fared? - Benzinga
Intellia Therapeutics' SWOT analysis: gene editing firm's stock faces pivotal trials - Investing.com
Gene-editing therapy aiding FAP patients year or more later: Trial - FAP News Today
Hereditary Angioedema Market Expected to Experience Major - openPR
Intellia Therapeutics: NTLA-2002 CRISPR-based therapy reduces rates of Hereditary Angioedema (HAE) attacks - 2 Minute Medicine
Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy - The Manila Times
Intellia's CRISPR Therapy Nex-Z Secures FDA RMAT Designation for Rare Disease Treatment | NTLA Stock News - StockTitan
Down 33% in 1 Month, Should You Buy the Dip With Intellia Therapeutics Stock? - sharewise
Drug developer stocks slide further in fall, despite gains from Exelixis and Xencor - BioWorld Online
Equities Analysts Offer Predictions for NTLA FY2025 Earnings - MarketBeat
Intellia Therapeutics price target lowered to $55 from $76 at Barclays - MSN
Intellia Therapeutics, Inc. (NTLA) Reports Q3 Loss, Tops Revenue Estimates - MSN
This Beaten-Down Stock Could Soar by 354%, According to Wall Street - AOL
CF Foundation invests $15M in Recode Therapeutics to boost CF gene editing - Cystic Fibrosis News Today
2.88%
2.65%
大文字化:
|
ボリューム (24 時間):